Advice
following an abbreviated submission:
paliperidone palmitate (Trevicta®) is accepted for use within NHS Scotland.
Indication under review: paliperidone palmitate (Trevicta®), a three-monthly injection, is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on one-monthly paliperidone palmitate injectable product.
This new formulation of paliperidone palmitate is administered every three months and is available at pro-rata cost to the monthly formulation.
Download detailed advice110KB (PDF)
Medicine details
- Medicine name:
- paliperidone (palmitate 3-monthly) (Trevicta)
- SMC ID:
- 1181/16
- Indication:
- Paliperidone palmitate (Trevicta®), a three-monthly injection, is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on one-monthly paliperidone palmitate injectable product.
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Central nervous system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 12 September 2016